EMA/605416/2012

European Medicines Agency decision

P/0209/2012

of 27 September 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftobiprole medocaril (sodium) (EMEA-000205-PIP02-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0209/2012

of 27 September 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral for ceftobiprole medocaril (sodium) (EMEA-000205-PIP02-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Basilea Pharmaceutica International Ltd. on 9 February 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 7 September 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ceftobiprole medocaril (sodium), powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ceftobiprole medocaril (sodium), powder for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Basilea Pharmaceutica International Ltd., Grenzacherstrasse 487, 4005 - Basel, Switzerland.

Done at London, 27 September 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/460085/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMEA-000205-PIP02-11

Scope of the application

Active substance(s):

Ceftobiprole medocaril (sodium)

Condition(s):

Treatment of pneumonia

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Basilea Pharmaceutica International Ltd.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Basilea Pharmaceutica International Ltd. submitted for agreement to the European Medicines Agency on 9 February 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 19 March 2012.

Supplementary information was provided by the applicant on 18 June 2012. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 7 September 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of pneumonia

2.1.1. Indication(s) targeted by the PIP

Treatment of nosocomial pneumonia

Treatment of community-acquired pneumonia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion

2.1.4. Studies

Area	Number of studies	Description
Quality	1	1. Development of age appropriate infusion solutions with concentrations higher than 2 mg ceftobiprole/mL for use in term and pre-term neonates.
Non-clinical	2	2. Subcutaneous Pilot Toxicity Study with an Intravenous Comparative Phase (TOX8087). 3. Subcutaneous Toxicity Study in Neonatal and Juvenile Albino Rats (TOX8611).
Clinical	4	4. Multicentre, open-label, single-dose, pharmacokinetic and tolerability study in children 3 months to less than 18 years of age. 5. Multicentre, randomised, investigator-blind, active controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard of care cephalosporin treatment in paediatric patients aged from 3 months to less than 18 years with nosocomial pneumonia or community-acquired pneumonia. 6. Open-label study to evaluate the single-dose pharmacokinetics and safety of ceftobiprole in neonates and infants up to 3 months of age. 7. Multicentre, open label study to evaluate the safety, tolerability, pharmacokinetics and efficacy multiple doses of ceftobiprole in term and pre-term neonates and infants up to 3 months of age with late-onset sepsis.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2016
Deferral for one or more studies contained in the paediatric investigation plan:	Yes